2024 December

Source : https://marijuanahealthreport.colorado.gov/literature-review/evidence-statements May 2018

Filed under: Cannabis/Marijuana,Health :
By Sherry Larson, People’s Defender –

“An ounce of prevention is worth a pound of cure.” Cliché – sure – truthful – absolutely! And when it comes to youth and alcohol, vaping and drug use, it is crucial to begin prevention efforts from an early age.

The Adams County Medical Foundation, under the direction of Sherry Stout, recognized a gap in youth prevention services and applied for a grant that focused on prevention. In 2015, a collective of professionals and retired professionals established a Data Prevention Committee to obtain information regarding youth drug, alcohol, vaping and tobacco usage. The Committee partnered with local schools and the Adams County Health Department to obtain data through surveys, resulting in a detailed database of information, including information on vaping, tobacco, and underage drinking.

The Committee recognized a need for more comprehensive funding to develop prevention strategies. Beginning in 2015, the Committee worked towards growing and qualifying for The Drug-Free Communities (DFC) grant, which supported their plans for future endeavors. “The Drug-Free Communities Support Program was created in 1997 by the Drug-Free Communities Act. Administered by the White House Office of National Drug Control Policy (ONDCP) and managed through a partnership between ONDCP and CDC, the DFC program provides grants to community coalitions to reduce local youth substance use.” (cdc.gov)

In October 2023, the Committee voted to form the Adams County Youth Prevention Coalition to meet the requirements to apply for DFC funds. The Coalition needed to be active for six months before applying for funding. The Coalition was mandated to have representatives from 12 community sectors who were not a part of the Medical Foundation. Those sectors are: Youth, Parents, Businesses Media, School, Youth-serving organizations, Law enforcement, Religious/fraternal organizations, Civic and volunteer organizations, Healthcare professionals, State, local, and Tribal governments and other organizations involved in reducing illicit substance use.

Three individuals will partner with the sectors to facilitate the grant: Tami Graham, Program Director; Billy Joe McCann, leader of the Youth Coalition; and Danielle Poe, the community’s only credentialed prevention professional, to represent education and school data collection through OHYES surveys.

In January 2024, The Adams County Youth Prevention Coalition hired Thrive Consulting to assist with the grant process. The grant application took extensive time and data to complete, resulting in an over 100-page document due and submitted in April 2024. Among demonstrating membership from the twelve sectors, the application required proof of consistent meetings and minutes showing that these representatives were actively working on strategizing prevention. Poe said, “A level of community readiness is expected.” Stout clarified that the funding is a community grant and should be led by the community and not isolated by a committee. Stout explained, “This is the first time Adams County qualified to receive the grant. It is a once-in-a-lifetime opportunity where significant funds are available to address prevention issues.”

The Coalition was notified in September 2024 that Adams County would receive the Drug-Free Communities Grant. Graham explained that the grant, which went into effect in October 2024, would reimburse $125,000 a year for 5 years of prevention work. Expecting a successful five years of prevention efforts, the Coalition would be eligible to reapply for a second term.

Poe and Graham discussed plans for the first year of executing the grant. Poe stated that the primary focus will be education, the Coalition’s learning responsibilities, and strategic planning for years two through five.

Carrying on with the Prevention Committee’s concentrations, the Coalition will examine data-proven prevention strategies, media campaigns, and differences between good and bad prevention techniques. In August 2025, the Coalition will submit a yearly progress report to the Drug-Free Communities Grant.

Stout said, “I would encourage widespread involvement of anyone who cares about our youth and their future.” The public is welcome to attend and share comments or concerns at Coalition meetings on the first Monday of every month. The sessions take place at noon in the FRS community room.

Source: https://www.peoplesdefender.com/2024/12/12/drug-free-communities-start-with-youth/

CDC warns of carfentanil, an opioid that’s 100 times more potent than fentanyl
by Fox News – Published Dec. 10, 2024, 11:13 a.m. ET
Originally Published by Centers for Disease Control

Fentanyl has made headlines for driving overdose deaths, but the and Prevention (CDC) is warning of the rise of an even deadlier drug.
Last year, nearly 70% of all U.S. overdose deaths were attributed to illegally manufactured fentanyls (IMFs).
One of those was carfentanil, an altered version of fentanyl that is said to be 100 times more potent, the CDC warned in a Dec. 5 alert.
Deaths from carfentanil rose by more than 700% in the past year, according to the same source — there were 29 deadly overdoses between January and June 2023, and 238 in that same time frame in 2024.
This data came from the CDC’s State Unintentional Drug Overdose Reporting System (SUDORS).
The numbers could actually be higher, as the 2024 data is preliminary and not all overdose deaths have been reported, the agency noted.
Since an outbreak of carfentanil-linked deaths in 2016 and 2016, the drug had “largely disappeared” until this recent reemergence, the CDC noted.
Based on the increase in fatal overdoses, the CDC is calling for “rigorous monitoring” of carfentanil and other opioids more potent than fentanyl.
Fentanyl has made headlines for driving overdose deaths, but the Centers for Disease Control and Prevention (CDC) is warning of the rise of an even deadlier drug.MOLEQL – stock.adobe.com
As with other illicit drugs, its “high profitability” likely drives its prevalence, according to Dr. Chris Tuell, clinical director of addiction services at the University of Cincinnati College of Medicine.
“Very small amounts can produce thousands of doses,” he told Fox News Digital.
“Synthetic opioids like carfentanil are relatively easy to manufacture in illicit labs,” Tuell went on. “Since the drug is a synthetic, it is easier to produce — unlike heroin, which is dependent on a plant like opium.”
Why is carfentanil so dangerous?
Carfentanil is 10,000 more times more potent than morphine and 100 times more potent than fentanyl, Tuell confirmed.
“Even a small amount can be fatal, as it can cause respiratory failure,” he said.
Last year, nearly 70% of all U.S. overdose deaths were attributed to illegally manufactured fentanyls (IMFs).Seth Harrison, The Journal News
One of the major concerns with carfentanil and fentanyl is that they are frequently mixed with other drugs, such as benzodiazepines, cocaine and opioids, which can lead to accidental overdoses, according to Tuell.
“Carfentanil can also resemble cocaine and heroin, so it blends right in with the other drugs,” he warned.
“Even a tiny amount can increase the potency of a drug mixture, leading to a stronger and longer-lasting high.”
Carfentanil often appeals to drug users who have a high tolerance to opioids because they seek a stronger substance, “making the drug attractive despite the risk,” Tuell noted.
How is the drug administered?
Carfentanil can be injected and is frequently mixed with other opioids or heroin, Tuell said. In a powder form, it can be inhaled.
“Inhaling the drug can be quickly risky because it can enter the bloodstream, resulting in an overdose,” Tuell warned. “This can happen intentionally or accidentally, as the drug can become easily airborne.”
Carfentanil can sometimes be in the form of “pressed pills” that resemble prescription medications, the expert said.
“Carfentanil can be lethal at the 2-milligram range depending on the route of administration,” he cautioned.
What parents should know
“Children are now the generation of artificial intelligence and deepfakes, as illicit drugs are posing like regular prescription medications,” Tuell cautioned.
To help protect kids from the dangers of illicit drugs, the expert emphasized the importance of open communication and education.
“Educate your child about the dangers and risks of drug use, including synthetic opioids like carfentanil,” he advised.
Parents should provide monitoring and supervision of their children, be aware of their social circles and limit unsupervised online activities, Tuell recommended.
“I also believe it is important that parents realize that 84% of individuals with a substance use disorder also have a co-occurring mental health issue,” he added.
Carfentanil often appeals to drug users who have a high tolerance to opioids because they seek a stronger substance, “making the drug attractive despite the risk,” Tuell noted.luchschenF – stock.adobe.com
“Seeking out mental health services for your child could help address the underlying issues that may have led to a substance use disorder.”
The CDC called for specific efforts in preventing deaths from illegally manufactured fentanyls, “such as maintaining and improving distribution of risk reduction tools, increasing access to and retention of treatment for substance use disorders, and preventing drug use initiation.”

Source: https://nypost.com/2024/12/10/us-news/cdc-warns-rise-in-opioid-thats-100-times-more-potent-than-fentanyl/

“I don’t think we’ve had truly robust public policy actions in the U.S. that we can point to that would have resulted in such a sudden and profound downturn in mortality,” says U. of I. health and kinesiology professor Rachel Hoopsick about the recent decline in drug-overdose deaths. “Although fentanyl-only deaths have declined, we’re seeing increases in deaths that co-involve fentanyl and stimulants, like methamphetamine. There have also been increases in nonopioid sedative adulterants, like xylazine.”

  • Editor’s notes:
    Hoopsick is lead author of the paper “Methamphetamine-related mortality in the United States: Co-involvement of heroin and fentanyl, 1999-2021.” The study is available online.

    DOI: 10.2105/AJPH.2022.307212

    To contact Rachel Hoopsick, email hoopsick@illinois.edu.

    Source: https://news.illinois.edu/view/6367/2075718277

EXECUTIVE HIGHLIGHTS
Today’s highly potent marijuana represents a growing and significant threat to public health and safety, a threat that is amplified by a new
marijuana industry intent on profiting from heavy use.
State laws allowing marijuana sales and consumption have permitted the marijuana industry to flourish, and in turn, the marijuana industry has influenced both policies and policy-makers. While the consequences of these policies will not be known for decades, early indicators are
troubling.
This report, reviewed by prominent scientists and researchers, serves as an evidence-based guide to what we currently observe in various states. We attempted to highlight studies from all the “legal” marijuana states (i.e., states that have legalized the non-medical use of marijuana). Unfortunately, data does not exist for several “legal” states, and so this document synthesizes the latest research on marijuana impacts in states where information is available

For more information please read the full information below:

2019LessonsFinal

Source: https://learnaboutsam.org/wp-content/uploads/2019/07/2019LessonsFinal.pdf July 2019

PBS Commentary:

Dec 1, 2024 3:51 PM EST

MEXICO CITY (AP) — It’s been called the closest the world has ever come to a vaccine against the AIDS virus.

The twice-yearly shot was 100 percent effective in preventing HIV infections in a study of women, and results published Wednesday show it worked nearly as well in men.

Drugmaker Gilead said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates — mostly in Africa, Southeast Asia and the Caribbean. But it has excluded nearly all of Latin America, where rates are far lower but increasing, sparking concern the world is missing a critical opportunity to stop the disease.

“This is so far superior to any other prevention method we have, that it’s unprecedented,” said Winnie Byanyima, executive director of UNAIDS. She credited Gilead for developing the drug, but said the world’s ability to stop AIDS hinges on its use in at-risk countries.

In a report issued to mark World AIDS Day on Sunday, UNAIDS said that the number of AIDS death last year — an estimated 630,000 — was at its lowest since peaking in 2004, suggesting the world is now at “a historic crossroads” and has a chance to end the epidemic.

The drug called lenacapavir is already sold under the brand name Sunlenca to treat HIV infections in the U.S., Canada, Europe and elsewhere. The company plans to seek authorization soon for Sunlenca to be used for HIV prevention.

While there are other ways to guard against infection, like condoms, daily pills, vaginal rings and bi-monthly shots, experts say the Gilead twice-yearly shots would be particularly useful for marginalized people often fearful of seeking care, including gay men, sex workers and young women.

“It would be a miracle for these groups because it means they just have to show up twice a year at a clinic and then they’re protected,” said UNAIDS’ Byanyima.

Such was the case for Luis Ruvalcaba, a 32-year-old man in Guadalajara, Mexico, who participated in the latest published study. He said he was afraid to ask for the daily prevention pills provided by the government, fearing he would be discriminated against as a gay man. Because he took part in the study, he’ll continue to receive the shots for at least another year.

“In Latin American countries, there is still a lot of stigma, patients are ashamed to ask for the pills,” said Dr. Alma Minerva Pérez, who recruited and enrolled a dozen study volunteers at a private research center in Guadalajara.

How widely available the shots will be in Mexico through the country’s health care system isn’t yet known. Health officials declined to comment on any plans to buy Sunlenca for its citizens; daily pills to prevent HIV were made freely available via the country’s public health system in 2021.

“If the possibility of using generics has opened, I have faith that Mexico can join,” said Pérez.

Byanyima said other countries besides Mexico that took part in the research were also excluded from the generics deal, including Brazil, Peru and Argentina. “To now deny them that drug is unconscionable.” she said.

In a statement, Gilead said it has “an ongoing commitment to helping enable access to HIV prevention and treatment options where the need is the greatest.” Among the 120 countries eligible for generic version are 18 mostly African countries that comprise 70 percent of the world’s HIV burden.

The drugmaker said it is also working on establishing “fast, efficient pathways to reach all people who need or want lenacapavir for HIV prevention.”

On Thursday, 15 advocacy groups in Peru, Argentina, Ecuador, Chile, Guatemala and Colombia wrote to Gilead, asking for generic Sunlenca to be made available in Latin America, citing the “alarming” inequity in access to new HIV prevention tools while infection rates were rising.

While countries including Norway, France, Spain and the U.S. have paid more than $40,000 per year for Sunlenca, experts have calculated it could be produced for as little as $40 per treatment once generic production expands to cover 10 million people.

Dr. Chris Beyrer, director of the Global Health Institute at Duke University, said it will be enormously useful to have Sunlenca available in the hardest-hit countries in Africa and Asia. But he said the rising HIV rates among groups including gay men and transgender populations constituted “a public health emergency” in Latin America.

Hannya Danielle Torres, a 30-year-old trans woman and artist who was in the Sunlenca study in Mexico, said she hoped the government would find a way to provide the shots. “Mexico may have some of the richest people in the world but it also has some of the most vulnerable people living in extreme poverty and violence,” Torres said.

Another drugmaker, Viiv Healthcare, also left out most of Latin America when it allowed generics of its HIV prevention shot in about 90 countries. Sold as Apretude, the bi-monthly shots are about 80 percent to 90 percent effective in preventing HIV. They cost about $1,500 a year in middle-income countries, beyond what most can afford to pay.

Asia Russell, executive director of the advocacy group Health Gap, said that with more than 1 million new HIV infections globally every year, established prevention methods are not enough. She urged countries like Brazil and Mexico to issue “compulsory licenses,” a mechanism where countries suspend patents in a health crisis.

It’s a strategy some countries embraced for previous HIV treatments, including in the late 1990s and 2000s when AIDS drugs were first discovered. More recently, Colombia issued its first-ever compulsory license for the key HIV treatment Tivicay in April, without permission from its drugmaker, Viiv.

Dr. Salim Abdool Karim, an AIDS expert at South Africa’s University of KwaZulu-Natal, said he had never seen a drug that appeared to be as effective as Sunlenca in preventing HIV.

“The missing piece in the puzzle now is how we get it to everyone who needs it,” he said.

Cheng reported from London.

 JooHee Yoon for Vox

Land of the free, home of the blazed.

How weed became America’s drug of choice | Vox

VOX Writer:  Marin Cogan         Dec 3, 2024

In the last few decades, marijuana’s had a major glow-up.

In 1992, less than 1 million people were using it daily or nearly every day — a low point, according to an analysis of data from the US National Survey on Drug Use and Health, which began surveying Americans in the 1970s. Ten times as many people, meanwhile, reported drinking alcohol daily or almost daily.

In the 1990s, weed was illegal nationally and in every state. But marijuana’s since had a major rebrand: Three decades later, it’s legal for recreational adult use in nearly half of the 50 states. Now, it’s even challenging alcohol for its status as America’s favorite daily intoxicant.In 2022, for the first time, more Americans were using marijuana daily, or near daily, than consuming alcohol at the same rate, according to a study by Jonathan Caulkins, a professor at Carnegie Mellon University. The number of daily or near daily marijuana users has grown from less than 1 million in 1992 to 17.7 million in 2022; in terms of per capita rate, that’s a 15-fold increase.

Marijuana is having a moment just as Americans reconsider their relationship toward alcohol. As public awareness of the toxic effects of even moderate alcohol consumption grows, many people are turning to THC products as an alternative. The THC industry touts its wares as a more natural alternative to alcohol with myriad health benefits, including decreased nausea, pain, and sleeplessness.

The rise in daily smokers (and vapers, and edible enjoyers, if you will) is also driven by the explosion of the industry. Millions of Americans live in cities and counties with retail shops offering a range of products that make the dimebags of yesteryear seem quaint by comparison: vape cartridges, edibles, oils, and waxes, offering more highly concentrated THC doses. The rise of marijuana retail has opened new doors for people who might have once shied away because they didn’t like smoking or were worried about breaking the law.

For many people, the rapid shift toward liberalization of marijuana policy, and the swiftness with which Americans have taken up consumption, has been great. But it’s also caught researchers off guard. Society has moved more quickly than they’ve been able to keep up with. That means millions of daily users are essentially conducting a real-time experiment on their own bodies. Marijuana isn’t benign for everyone, though. Some of the results of the real-time experiment are already becoming apparent, both to regular users and people working in health care.

“It is very desirable to believe that there is a drug that can make you feel good, that can relax you, and has absolutely no negative outcomes,” says Dr. Nora Volkow, director of the National Institute on Drug Abuse at the National Institutes of Health. “But in biology, there are no free lunches.”

Take the emergence of cannabinoid hyperemesis syndrome, a condition marked by intense and prolonged bouts of nausea and vomiting and brought on by regular, long-term marijuana use. While once extremely rare, some doctors are saying they now see patients with symptoms frequently. “It emerged because people were consuming marijuana regularly with high [THC] content,” Volkow says. “And similarly, there is now evidence that consumption in those patterns is associated with higher risk of stroke or cardiovascular disease.”

Maybe the most worrying studies about frequent, heavy marijuana use involve teens and young adults. (While experts say marijuana use appears to be less risky for middle-aged adults, there’s still a lot they don’t know that needs to be researched further. Some note that more research is needed on older adults in particular.) Studies show regular marijuana use among adolescents and teens can predict increased risk of the development of schizophrenia and other psychotic disorders. Others have shown an increased likelihood of depression and suicidal ideation, disrupted dopamine function, and disruptions in the anatomy of the brain.

And marijuana, contrary to popular belief, can be habit forming. It can also increase the risk of dependence on other substances. A recent analysis by Columbia University for the New York Times estimated that as many as 18 million people in the US may have some form of cannabis use disorder, or addiction.

Getting a handle on who might be harming their health is tricky. Even the findings that point to a major rise in daily users leave a lot of questions unanswered, especially around how often they’re smoking, vaping, or ingesting, and how potent the THC is.

Caulkins, the Carnegie Mellon professor who published the research showing that more Americans are using marijuana daily, says there are different categories of daily or near daily users. There are the people who use marijuana similar to the way someone might pop a melatonin before going to bed at night — a small, daily dose to help with sleep or pain. And then there are those who are more like heavy cigarette smokers, consuming marijuana multiple times a day, morning or night, before or after meals, on breaks from work, or out with friends.

His previous research has found that daily or near daily users are a small portion of overall users, but make up about three-quarters of all marijuana purchases.

But just how many of the 17.7 million daily or near daily marijuana users are truly heavy users remains a mystery, because the US National Survey on Drug Use and Health doesn’t ask about how many times a day someone is using, or what they’re taking.

“We can have people who are using near daily, but they’re taking a puff off their vape pen right before they go to sleep,” says Ziva Cooper, a researcher and director for the UCLA Center for Cannabis and Cannabinoids, “versus somebody who’s using daily or near daily and they’re using five to 10 one-gram pre-rolls every day. You can imagine that the health outcomes are going to be quite different.”

It’s not just that researchers are often unsure of how much people are taking. The consumers are also often not sure what they’re putting in their bodies. That’s partly because what’s being sold in stores is way stronger than the weed that millennials and previous generations grew up with. Over the last 25 years, government data shows, the percentage of THC in marijuana seized by the Drug Enforcement Agency (DEA) has more than tripled, from 5 percent to 16 percent. And a lot of the products for sale in dispensaries can be even more potent — with vendors selling concentrated products, some claiming 90 or close to 100 percent THC. Some teens who’ve used those products have struggled with vomiting and substance abuse.

Cooper says it’s not uncommon for her to end up on the phone with her patients as they read the label aloud to her and she searches the internet to try to find out what exactly they’re taking.

“As researchers,” Cooper says, “we are trying to catch up with what’s actually happening in the world of cannabis. And we are woefully behind.”

Though humans have been using cannabis for at least 10,000 years — it was widely used for medical purposes in the United States in the late 19th century — the demonization of marijuana under the Nixon administration in the 1970s pushed the plant into the shadows.

Nixon, according to secretly reported tapes, knew at the time that marijuana was “not particularly dangerous.” But his “war on drugs,” carried on by the administrations of Ronald Reagan, George H.W. Bush, and Bill Clinton forced consumers and their providers to stop or risk arrest.

The drug’s public image was less threatening — smoking pot was played for laughs in movies and TV shows — but the reality of its criminalization was much darker. Hundreds of thousands of people were arrested and incarcerated each year for selling and dispensing marijuana, with the harms falling disproportionately on Black people.

Public awareness of the harms caused by criminalizing marijuana grew, and so too did a movement to raise awareness about the medicinal benefits of its use, especially for chemotherapy and cancer parents, who found marijuana use helpful for combatting nausea. Meanwhile, advocates focused on reducing mass incarceration and addressing racial disparities in the judicial system pushed states to begin decriminalizing marijuana and revising the sentences for people serving time for it. After getting the states to approve marijuana for medicinal purposes, organizations began pushing for it to be legal for all adults. Today, marijuana is legal for medical use in 38 states and for recreational use for adults in roughly half of the states, plus the District of Columbia.

But marijuana is still illegal on the national level, where it is classified as a Schedule I drug — meaning the government doesn’t recognize it for medical use. That’s made getting the safety approvals and government funding necessary to study the drug difficult. Researchers say it’s made it harder to study potential risks of long-term marijuana use. But it’s made it harder to study the potential benefits, too. Earlier this year, the Biden administration proposed changing marijuana to a Schedule III, which will put it in a lower-risk category with drugs like ketamine.

In 2022, President Joe Biden signed the Medical Marijuana and Cannabidiol Research Expansion Act, hoping to reduce some of the federal barriers that have stymied research in the past. The legislation required the DEA to register and approve more researchers, and more manufacturers who can provide them with marijuana or cannabidiol (CBD). In addition to creating more opportunities and resources for researchers, the bill asked the DEA to assess whether there is enough marijuana to meet researchers’ experimental needs, and allowed doctors to discuss the benefits and harms of marijuana with their patients.

The federal government’s approach to marijuana has also meant that each state is doing its own regulation of its markets, without a concrete set of federal safety guidelines. The piecemeal nature of legalization, absence of national regulation, and lack of public awareness has contributed to the uncertainty around marijuana use and its long-term consequences.

The market is also changing rapidly. The 2018 farm bill, for example, legalized hemp, which inadvertently popularized delta-8 THC. Delta-8 THC, which is similar to delta-9 THC, is less potent in its natural form, but producers have been able to extract and synthesize the delta-8 THC in hemp, converting it into more potent concentrates. Manufacturers are now selling products the FDA says have serious health risks. But that isn’t the only thing that the government can and should be doing.

In September, the National Academies of Sciences, Engineering, and Medicine issued a report outlining what state and federal governments could do to establish better public policy around marijuana and minimize potential negative public health consequences over the next five years.

The report outlined specific actions, such as closing the loophole in the 2018 farm bill that legalized delta-8 THC and clarifying that all forms of THC are subject to regulation under the Controlled Substances Act. More broadly, the report calls for states that have legalized, public health officials, and government agencies like the CDC to come together and establish more unified guidelines for marijuana, working to develop a set of regulations around the production and sale. Marijuana, the report argues, should be regulated the same way as alcohol and tobacco.

The report also recommends that the federal government support more research into marijuana use, along with a public health campaign to educate people about individual risks for different populations, including teens and older people.

It’s a tall order, but even that doesn’t capture everything researchers want to know. Caulkins, for one, has other questions.

“Cannabis intoxication impairs short-term memory formation. When cannabis was only being used as a social drug on weekends, who cares if it reduced effective performance on intellectual tasks?” he says. “Now, roughly half of cannabis is consumed by people who use often enough that they spend perhaps 50 percent of their waking hours under the influence of the drug. A lot of those hours of cannabis intoxication are while people are on the job or in school. How does that impact your functioning, how much you’re learning in college? We underinvest in thinking about the consequences of so many billions of hours of work and school time being, in some form, under the influence.”

It’s a question that might be hard to answer empirically right now. But it matters — maybe most of all for the millions of people taking part in America’s real-time marijuana experiment. “Maybe it’s not a problem,” Caulkins says. “But possibly, it’s affecting people’s abilities to meet their life goals in some subtle ways.”

Source: https://www.vox.com/the-highlight/379637/marijuana-daily-drug-americans-alcohol

Filed under: Cannabis/Marijuana,USA :

Emphatic Rejection by DrugWatch International

COMMENT BY JOHN J. COLEMAN Ph.D, PRESIDENT, DRUGWATCH INTERNATIONAL – 01 December 2024 

From: drug-watch-international@googlegroups.com

The proposal from the Secretary of HHS and the Attorney General to reschedule marijuana from Schedule I to Schedule III – responding to President Biden’s request to take a second look at marijuana scheduling – is probably DOA at this point. The hearing at DEA tomorrow is closed except to media and designated participants (apparently, though, it will be online for the public). They may go through some of the motions because that’s what they are supposed to do, but the usual time of several months to go from hearing to Final Order or Final Rule will place the resolution of this matter well into the next administration. When there’s a change of parties, as in this case, the new administration is not eager to adopt or implement the changes or proposals of the old one.

The current move to reschedule marijuana amount to a political hoax because Congress is not about to add the number of federal employees that would be needed to enforce a Schedule III status for marijuana. Every “dispensary” in all the states (est. 38 of 50, plus D,C.) would immediately or within a time set by a Final Rule must register with DEA, pay a registration fee, meet certain requirements, before being able to fill and dispense valid prescriptions for marijuana. The Controlled Substances Act imposes strict controls on imports and exports of controlled substances, as well as its packaging, labeling, distribution, and storage.

The federal government that in 1993 abdicated its responsibility for controlling marijuana (per the infamous Cole Memorandum) has neither the resources nor the desire to enforce new marijuana provisions of the CSA because it no longer enforces even a modicum of the old ones. This is nothing but a cruel joke perpetrated by insincere leaders contemptuous of those who disagree with them. The DEA administrator refused to sign the Notice of Proposed Rulemaking leaving the Attorney General to regain his authority and issue the NPRM in the form of an Attorney General’s Order. That, alone, disqualifies this rescheduling exercise, assuming, that is, that this lunacy ever reaches a judicial review.

As for tomorrow’s meeting at DEA’s administrative law court, I think it will be perfunctory and simply set the agenda for the following two or three months when there may be a hearing. I say “may” because the incoming AG and DEA administrator could very well put the kibosh on this nutty move by the Biden administration. As our late friend and colleague Otto Moulton used to say, “read what the other side is saying!” According to Cannabis.net, a pro-marijuana website, the headline of their alarming article says it all: “Trump’s Not So Cannabis Friendly Cabinet Picks – His VP, AG, Head of the CDC and FDA Nominees all Hate Legal Weed: The cannabis scorecard for Trump’s new cabinet is not shaping up well for legalization fans!”

That pretty much says it all.

John Coleman

************************

Submission by Maggie Petito to DrugWatch International –  mlp3@starpower.net
Sent: Sunday, December 1, 2024 7:21 AM
To: drug-watch-international@googlegroups.com
Subject: Chronister12-1-24

From The Washington Post: “ Chronister would enter an agency that has been roiled by the convictions of several former agents in corruption cases and scrutiny of Milgram’s hiring practices.

The incoming DEA administrator will also helm the agency as it handles a Biden Justice Department proposal to loosen restrictions on marijuana — a measure supported by Trump despite objections from other GOP leaders…

The Justice Department has proposed to reclassify marijuana from a tier reserved for substances such as heroin and LSD. The move to reclassify marijuana would not legalize the drug but would move it to Schedule III, a category that includes prescription drugs such as ketamine, anabolic steroids and testosterone. The proposal met pushback internally at the DEA, which questioned whether reclassification violated international treaty obligations regarding drug control and if a federal health agency used the wrong legal standard in making its determination, according to a Justice Department legal opinion that sided with the Department of Health and Human Services. When officials submitted the proposed rule to reclassify marijuana in April, the paperwork was signed by Attorney General Merrick Garland, not Milgram.

The marijuana proposal will be considered in DEA administrative court; a preliminary hearing is scheduled for Monday, 2nd December 2024.  The proposal, if it goes through, would not be finalized until after Trump becomes president.”

************************

Washington Post     David Ovalle and Anumita Kaur    November 30, 2024                    Hillsborough Sheriff Chad Chronister picked to lead DEA under Trump – The Washington Post

President-elect Donald Trump on Saturday tapped Hillsborough County Sheriff Chad Chronister to lead the Drug Enforcement Administration, replacing Anne Milgram.

The incoming DEA administrator will also helm the agency as it handles a Biden Justice Department proposal to loosen restrictions on marijuana — a measure supported by Trump despite objections from other GOP leaders.

The Justice Department has proposed to reclassify marijuana from a tier reserved for substances such as heroin and LSD. The move to reclassify marijuana would not legalize the drug but would move it to Schedule III, a category that includes prescription drugs such as ketamine, anabolic steroids and testosterone.

The proposal met pushback internally at the DEA, which questioned whether reclassification violated international treaty obligations regarding drug control and if a federal health agency used the wrong legal standard in making its determination, according to a Justice Department legal opinion that sided with the Department of Health and Human Services. When officials submitted the proposed rule to reclassify marijuana in April, the paperwork was signed by Attorney General Merrick Garland, not Milgram.

The marijuana proposal will be considered in DEA administrative court; a preliminary hearing is scheduled for Monday. The proposal, if it goes through, would not be finalized until after Trump becomes president.

Source: COMMENT BY JOHN J. COLEMAN Ph.D, PRESIDENT, DRUGWATCH INTERNATIONAL

The findings are still valid as to why marijuana should not be rescheduled as determined in the Denial of Petition To Initiate Proceedings To Reschedule Marijuana, by the Drug Enforcement Administration (DEA), 81 FR 53767-01(August 12, 2016)

Human Physiological and Psychological Effects of Marijuana

MARIJUANA AND MENTAL ILLNESS

Recent studies show a connection between marijuana use and mental illness. In 2017, the National Academy of Sciences (NAS) concluded after a review of over 10,000 peer-reviewed academic articles, that marijuana use is connected to mental health issues (like psychosis, social anxiety, and thoughts of suicide). [1]

A study discussed in an October 2017 Scientific American shows that people who had consumed marijuana before age 18 developed schizophrenia approximately 10 years earlier than others. The more marijuana you take – and the higher the potency – the greater the risk. [2]

A November 2017 report on a study found that marijuana use in youth is linked to bipolar symptoms in young adults. [3]

References

[1] Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research.
http://nationalacademies.org/hmd/~/media/Files/Report%20Files/2017/Cannabis-Health-Effects/Cannabis-chapter-highlights.pdf

[2] https://www.scientificamerican.com/article/link-between-adolescent-pot-smoking-and-psychosis-strengthens/

[3] http://www.newswise.com/articles/view/685947/?sc=dwtn November 2017

THERE IS A LINK BETWEEN MARIJUANA USE AND OPIATE USE

Marijuana use is associated with an increased risk for substance use disorders. [1] Marijuana use appears to increase rather than decrease the risk of developing nonmedical prescription opioid use and opioid use disorder. [2] In 2017, the National Academy of Sciences (NAS) landmark report written by top scientists concluded after a review of over 10,000 peer-reviewed academic articles, that marijuana use is connected to progression to and dependence on other drugs, including studies showing connections to heroin use. [3]

New research suggests that marijuana users may be more likely than nonusers to misuse prescription opioids and develop prescription opioid use disorder. The investigators analyzed data from more than 43,000 American adults. The respondents who reported past-year marijuana use had 2.2 times higher odds than nonusers of meeting diagnostic criteria for prescription opioid use disorder. They also had 2.6 times greater odds of initiating prescription opioid misuse. [4]

References

[1] JAMA Psychiatry. 2016 Apr;73(4):388-95. doi: 10.1001/jamapsychiatry.2015.3229.
Cannabis Use and Risk of Psychiatric Disorders: Prospective Evidence From a US National Longitudinal Study. Blanco C1, Hasin DS2, Wall MM2, Flórez-Salamanca L3, Hoertel N4, Wang S2, Kerridge BT2, Olfson M2. https://www.ncbi.nlm.nih.gov/pubmed/26886046

Cadoni C, Pisanu A, Solinas M, Acquas E, Di Chiara G. Behavioural sensitization after repeated exposure to Delta 9-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology (Berl). 2001;158(3):259-266. Available from: https://www.researchgate.net/publication/11640927_Behavioral_sensitization_after_repeated_exposure_to_D9-tetrahydrocannabinol_and_cross-sensitization_with_morphine

[2] Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States, Mark Olfson, M.D., M.P.H., Melanie M. Wall, Ph.D., Shang-Min Liu, M.S., Carlos Blanco, M.D., Ph.D. Published online: September 26, 2017at: https://doi.org/10.1176/appi.ajp.2017.17040413

[3] Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research. See: http://nationalacademies.org/hmd/~/media/Files/Report%20Files/2017/Cannabis-Health-Effects/Cannabis-chapter-highlights.pdf

[4] https://www.drugabuse.gov/news-events/news-releases/2017/09/marijuana-use-associated-increased-risk-prescription-opioid-misuse-use-disorders

MARIJUANA USE BEFORE, DURING OR AFTER PREGNANCY CAN CAUSE SERIOUS MEDICAL CONDITIONS

Prenatal marijuana use has been linked with:

1. Developmental and neurological disorders and learning deficits in children.
3. Premature birth, miscarriage, stillbirth.
4. An increased likelihood of a person using marijuana as a young adult.
5. The American Medical Association states that marijuana use may be linked with low birth weight, premature birth, behavioral and other problems in young children.
6. Birth defects and childhood cancer.
7. Reproductive toxicity affecting spermatogenesis which is the process of the formation of male gamete including meiosis and formation of sperm cells.

References

Volkow ND, Compton WM, Wargo EM. The risks of marijuana use during pregnancy. JAMA. 2017;317(2):129-130.

https://www.drugabuse.gov/publications/research-reports/marijuana/letter-director

https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Marijuana-Use-During-Pregnancy-and-Lactation

Source: Email from Dave Evans to Drug Watch International April 2018

Attached is a submission from Professor Stuart Reece to the Food and Drug Administration in USA for forwarding to the World Health Organization relating to the re-scheduling of cannabis

FDA Federal Register Submission for WHO Review and Consideration – Colorado Teratogenicity Patterns Illustrated

Email from Stuart Reece April 2018

Medical research can sometimes become disconnected from the interests and needs of the people it is intended to serve. This is true across diseases and disorders, and addiction research is no exception. Too often, scientists who study drugs and addiction have not meaningfully engaged people with lived and living experience of substance use. And when people who use substances are engaged, the experience may leave them feeling exploited or traumatized, such as when they are not adequately compensated for their time or when they are asked to recall distressing life events. It is also rare for researchers to follow up with participants to let them know what was learned in a research project.

Such experiences contribute to a feeling that research is a one-way transaction benefiting scientists but giving little back to the community. Lack of meaningful community engagement also compromises the quality of the science by not incorporating the valuable ideas and insights of people who use drugs.

NIDA is committed to improving community engagement in all parts of the research process. For that reason, we have asked the National Advisory Council on Drug Abuse (NACDA)—the body of experts that advises on NIDA’s scientific research priorities—to convene a working group to recommend ways to enhance the meaningful engagement of people who have experience with drug use in the research our Institute funds. The workgroup will inform the creation of resources that outline NIDA’s expectations regarding community engagement and help both applicants and community partners navigate this critical work.

NIDA has long encouraged community-engaged research, and it is required element in various NIDA research funding opportunities, including those supported through our Racial Equity Initiative. The evolving opioid overdose crisis has underscored the importance of ensuring that people’s lived experience of substance use is centered in the science we support. For example, one of the pillars of the NIH Helping to End Addiction Long-term (HEAL) Initiative is that research must be relevant and responsive to the individuals, families, and communities it aims to help. One way HEAL studies are doing this is by drawing on the input of community advisory boards to ensure that the research is best tailored to the needs of the people most impacted by it.

The NIDA-funded Harm Reduction Research Network is a nationwide set of projects to enhance the impact of harm-reduction efforts, and its community advisory boards have already helped shape some of the studies. One project involves the development of a survey instrument to capture experiences of people who use drugs, and advisory board members helped tailor the wording of the instrument so that it reflected language more likely to be used by people who use drugs. Another study aimed at reducing overdose and increasing engagement in harm reduction and treatment services had originally been limited to people who use methamphetamine. Based on the input of advisors with more up-to-date knowledge of drug-use in their community, the study was broadened to include people who use cocaine, as that was identified as an emerging stimulant in their area.

The Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR) project is addressing the needs of people with substance use disorders and pain via a network of multidisciplinary team science collaborations. Its community advisory boards weigh in on funding decisions for pilot studies, and some of these studies have included a community partner as a co-investigator. Based on community input about the important role of PTSD and discrimination in healthcare settings in pain and opioid misuse and addiction, IMPOWR researchers added PTSD and stigma/discrimination items to their common data elements (the standardized questions that facilitate data-sharing across studies).

The Native Collective Research Effort to Enhance Wellness (NCREW) Initiative is partnering with Tribal organizations to support community-driven research projects that address opioid misuse and pain in Native communities. By providing needed training, technical assistance, and tools, the NCREW project is building capacity within Native communities to conduct locally prioritized research that incorporates indigenous knowledge and lived experience, with the aim of building effective, sustainable, and strengths-based interventions.

As outlined in NIDA’s Strategic Plan, NIDA is committed to partnering with people with lived and living experience in the development of new treatments for substance use disorder. Consistent with that goal, NIDA is funding four Patient Engagement Resource Centers (PERCs) to test various models of patient engagement that can inform research on SUD treatment services. Each PERC will recruit members of a particular patient population to understand what prevents them from finding or receiving evidence-based treatment services. This information will be used to pilot test patient-informed solutions to these challenges that can ultimately serve as models for the development of interventions in other settings.

There are many other ways that partnering with people with living experience of substance use could benefit both science and the community. Surveillance is one example. The drug market is rapidly changing, and people who actively use drugs and live this reality are best poised to provide information on the drug supply and its effects. And through their engagement in surveillance efforts, participants could gain information on new adulterants and contaminants that could help inform their own decisions.

In these, as with other research efforts, people who use drugs need to be treated with respect, and their confidentiality must be protected. They must also be compensated fairly for their time, their input, and their commuting and childcare costs.

Including people with experience of substance use and addiction in the scientific workforce—and making sure they feel safe and recognized as valuable members of the research team—must also become a priority for our science. As some of my colleagues at NIDA’s Intramural Research Program argued two years ago in the Journal of Addiction Medicine, people with lived and living experience of substance use disorders have unique perspectives that are invaluable in making sure that the right research questions are asked.

These are just some of the possible topics that may be discussed in the new NACDA workgroup. For that group, we are seeking individuals who identify as having experience with substance use or a substance use disorder or as a family or caregiver of someone who does. Participants will meet virtually three or four times during 2025 and potentially early 2026 and will be compensated for their time during the meetings. If you are interested in participating, further information is available on the Council Workgroups page. We are accepting application statements through January 10, 2025.

Associated links:

<https://links-1.govdelivery.com/CL0/https:%2F%2Fwww.facebook.com%2FNIDANIH/1/010001935f514dad-3bc896f6-09a3-4a99-9a57-650fc67cd8ad-000000/gZawcxuqmqpVxlDYl5KRA6aAb0F6qaVMf-PxgI6LnuI=380>  <https://links-1.govdelivery.com/CL0/https:%2F%2Fx.com%2FNIDAnews/1/010001935f514dad-3bc896f6-09a3-4a99-9a57-650fc67cd8ad-000000/mpqUEYpIuhc9JFHxEKtJYgd0sO2MkRK2lTyjYLfCx1E=380>  <https://links-1.govdelivery.com/CL0/https:%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-national-institute-on-drug-abuse-nida/1/010001935f514dad-3bc896f6-09a3-4a99-9a57-650fc67cd8ad-000000/MDAOeV4b9UqgdTQKqsv8NP1IxaNy1-VJZf0pPGIdSLM=380>  <https://links-1.govdelivery.com/CL0/https:%2F%2Fwww.youtube.com%2Fuser%2FNIDANIH/1/010001935f514dad-3bc896f6-09a3-4a99-9a57-650fc67cd8ad-000000/XDdTYlTHjOr7nahEQDBsHClsGu3q7NdUBzatmgv6P7E=380>

 

Source: Forwarding Agency:

Herschel Baker, International Liaison Director & Queensland Director

Drug Free Australia

Web: https://drugfree.org.au/

mailto:drugfreeaust@drugfree.org.au

mailto:drugfree@org.au

Policy News Roundup: November 14, 2024

by drugfree.org

The main point: Overall, a Trump administration is likely to be more focused on law enforcement and supply side responses to the overdose crisis, rather than approach the challenge from a public health perspective.

The details:

  • Treatment: We do not expect there will be efforts to remove barriers and expand access to methadone. There could be some efforts to expand buprenorphine (particularly telemedicine models).
  • Harm Reduction: Harm reduction received unprecedented federal support under the Biden administration. It is unlikely that such support will continue. Efforts to expand naloxone distribution may continue, but other harm reduction strategies (e.g., syringe service programs, overdose prevention sites) are not likely to receive support in a Trump administration.
  • Criminal Legal System: The use of Medicaid to provide medications for opioid use disorder in jails/prisons will likely face increased scrutiny. As part of a broader effort to limit Medicaid costs, a Trump administration may push to restrict federal funding for these programs. Drug courts and diversion programs will likely continue to receive support.
  • Insurance: There could be major changes to the Affordable Care Act (ACA), which includes some of the strongest insurance protections available for addiction, and Medicaid, which covers more addiction treatment than any other insurer. The enhanced ACA premium subsidies that led to record levels of insurance enrollment are not likely to be extended after they expire next year, and there may be efforts to slash funding for enrollment outreach, promote short-term health plans with skimpier coverage and allow insurers to charge sicker people higher premiums. Medicaid is likely to be targeted for funding cuts, and the Trump administration is likely to revive efforts to implement work requirements for Medicaid coverage.
  • Marijuana: It is not clear what a Trump administration will mean for marijuana. While previously strongly opposed to easing restrictions, Trump more recently came out in support of the legalization initiative in Florida (his home state) and the Biden administration’s push to reschedule marijuana.
  • Penalties: A Trump administration could push for harsher penalties for drug offenses.
  • Drug Trafficking: Combatting drug trafficking is likely to be the main focus for the administration on this issue. Rhetoric will likely focus on the U.S.-Mexico border, even though evidence has shown that most drugs are brought into the U.S. at legal ports of entry by U.S. citizens. There is likely to be continued pressure on Mexico and China for their role in fentanyl and precursor trafficking.
  • Federal Agencies: If the Trump administration takes action on plans to scale back federal agencies, it could lead to a reduced role for the Office of National Drug Control Policy, potentially in favor of the Department of Justice or Drug Enforcement Administration. Department of Health and Human Services agencies are also likely in for budget cuts and major changes in authority and focus, which could reduce the role of health agencies like the Centers for Disease Control and Prevention, the National Institutes of Health and the Food and Drug Administration in addressing the addiction crisis and the funding available to do so.

Why it’s important:

  • Federal funding for addiction has remained stable but shifts between law enforcement/interdiction and treatment, depending on the administration’s priorities. An increased focus on law enforcement/interdiction could mean less funding and focus on treatment. Funding for prevention has remained small and relatively the same.

A caveat: It is early. Trump’s campaign did not focus heavily on policy proposals or on this issue, and we do not know yet who will be appointed to top health roles in the administration.

In the states: drug policy backlash

Several states also had drug-related ballot initiatives on their ballots this election.

The main point: In recent elections, ballot measures focused on liberalizing drug policies (e.g., legalizing marijuana, decriminalizing drugs) have passed. This time, however, these types of measures failed, signaling concerns about these drug policies.

The details:

  • Marijuana: Florida, North Dakota and South Dakota all rejected measures to legalize recreational marijuana. Nebraska did approve a measure to legalize medical marijuana, but a judge could invalidate the results due to a pending lawsuit. Opponents cited concerns about crime, addiction and becoming like liberal states that have legalized marijuana. While most Americans continue to support marijuana legalization, the downsides of marijuana production and negative health impacts of high-potency marijuana and teen use have recently been in the spotlight.
  • Psychedelics: Massachusetts rejected a measure to legalize therapeutic use of certain psychedelics (psilocybin, psilocin, DMT, ibogaine, mescaline). Voters in more than a dozen Oregon cities also voted to ban sales and use of psilocybin, after the state approved licensed psilocybin treatment centers four years ago. Psychedelics have gained increased support across the political spectrum, but concerns are growing about allowing psychedelics to proliferate before there has been adequate research.
  • Penalties: California passed a measure to repeal a 2014 ballot initiative that had lessened penalties for certain drug offenses. The new measure reclassifies certain theft- and drug-related crimes as felonies, rather than misdemeanors. It also establishes court-mandated treatment for those with repeat drug offenses. Voters perceive social disruption from public drug use and want more law and order.

Another thing: Daniel Lurie won his race to be mayor of San Francisco, beating incumbent London Breed. Much of the campaign focused on debates about how to address public drug use in the city. Lurie ran on promises to expand police staffing, build more homeless shelter beds and shut down open-air drug markets.

Why it’s important: This is part of the broader recent backlash toward efforts to liberalize drug policies and emphasize treatment and harm reduction over punitive responses.

  • Increases in visible homelessness, mental illness and substance use following COVID, the rise of fentanyl and the continuing high level of overdose deaths have led many to feel that recent efforts are not working. This is exacerbated by rhetoric tying “failed” drug policies to supposed spikes in crime and drug use.

 

California report warns of high-potency marijuana health dangers

What’s new: A report by scientists convened by the California Department of Public Health suggests that state policymakers must do more to warn consumers of the health dangers of high-potency marijuana and deter its use.

The background:

  • Most of the marijuana sold in California is high potency, with a concentration of THC five to ten times greater than the marijuana of the 1970s and 1980s.
  • High-potency marijuana is more likely to be addictive and cause serious health problems, like psychosis or cannabis hyperemesis syndrome.

The takeaways: The authors say policymakers should take lessons from successful campaigns to reduce smoking and drinking. Among other ideas, they recommend:

  • Restricting marijuana advertising, packaging and marketing
  • Barring flavored products that appeal to kids
  • Limiting THC content
  • Raising taxes on high-potency products
  • Launching a public education campaign about high-potency marijuana’s health effects

What’s next: The authors say they are lobbying the California Department of Public Health, the California Department of Cannabis Control, the state legislature and other state agencies to boost regulation.

 

Source: https://drugfree.org/drug-and-alcohol-news/policy-news-roundup-november-14-2024/

Workplaces have a unique opportunity to make subtle yet meaningful adjustments to better support employees who may be in recovery or experiencing challenges. When businesses make small changes in their events, management style, and overall culture, they create an environment that respects and uplifts employees facing SUDs. Here are three impactful ways to make the workplace more welcoming:

# 1: Host Inclusive Gatherings with Non-Alcoholic Options

Work events can inadvertently center around alcohol, creating uncomfortable situations for employees who don’t drink and/or are in recovery. Making a few simple shifts can help ensure everyone feels included:
• Avoid holding meetings in bars or pubs. Instead, choose locations that aren’t centered on alcohol, such as coffee shops, casual restaurants, or outdoor spaces.
• Offer a variety of non-alcoholic drinks that are as enjoyable as alcoholic options. These could include mocktails, sparkling water with unique flavors, or other festive drinks. This small touch shows thoughtful consideration and signals that the event is meant for everyone.
• Consider alcohol-free events. Not every event needs to feature alcohol to be fun. Think of team-building activities like escape rooms, game nights, or cooking classes, which naturally focus on engagement without the need for alcohol.

#2: Encourage Supervisors to be Allies

Supervisors play a critical role in creating a compassionate, supportive workplace. By actively supporting employees rather than judging them, supervisors can contribute significantly to a culture of empathy and openness. Here’s how they can help:
• Listen without judgment. If an employee opens up about their challenges, supervisors should approach the conversation with empathy, focusing on support rather than consequences, while of course maintaining safety.
• Respect privacy and confidentiality. Supervisors should reassure employees that their personal issues will remain private and will only be discussed on a need-to-know basis, which helps foster trust.
• Share personal experiences if appropriate. For supervisors in recovery, sharing their stories can inspire others, showing that it’s possible to face challenges and succeed. Authentic, relatable leadership can be incredibly powerful for employees who may feel isolated.

#3: Encourage Coworkers to Support Each Other

Sometimes, coworkers are the first to notice changes in behavior or attendance. They can be crucial sources of support, helping to create a culture that’s proactive and understanding:
• Encourage open, honest communication. Rather than approaching a struggling coworker with judgment, a simple “I’m here if you need anything” can make a huge difference.
• Assist with resources. Coworkers can help each other navigate employment policies, find helpful information, or locate support groups if needed. Being informed and sharing resources can be invaluable.
• Respect boundaries and avoid gossip. Gossip or speculation only adds stigma to those facing SUDs. A culture of respect encourages coworkers to redirect conversations if someone starts gossiping or making assumptions about another’s struggles. For more on the importance of language on stigma, check out the National Institute of Drug Abuse’s resource, Words Matter as well as Drug Free America Foundation’s resource on Stigma here.

These small adjustments—hosting inclusive events, training supervisors as allies, and encouraging a supportive culture among coworkers—can help a business become a welcoming, stigma-free environment for employees with SUDs working towards recovery. By focusing on inclusivity, empathy, and respect, workplaces can create meaningful, positive changes that support both individual well-being and the company’s overall success.

Sources:

Drug Free America Foundation, Inc. “Stigma.” https://www.dfaf.org/wp-content/uploads/2024/09/Stigma-2024.pdf

O’Connor, P., PhD. (2023, November 23). Human resource departments can help or hinder employees with SUDs. Psychology Today. https://www.psychologytoday.com/us/blog/philosophy-stirred-not-shaken/202311/substance-use-disorders-and-the-work-place

Words matter: preferred language for talking about addiction | National Institute on Drug Abuse. (2023, November 15). National Institute on Drug Abuse. https://nida.nih.gov/research-topics/addiction-science/words-matter-preferred-language-talking-about-addiction

 

One in 3 adults who responded to a new nationwide survey said they had suffered “secondhand harm” from another person’s drinking, and more than 1 in 10 said a loved one’s drug use had harmed them. PHI’s William Kerr shares insights on how secondhand harms from alcohol and drug use can affect families, relationships and communities.

“Think of it as collateral damage: Millions of Americans say they have been harmed by a loved one’s drug or alcohol use.

One in 3 adults who responded to a new nationwide survey said they had suffered “secondhand harm” from another person’s drinking. And more than 1 in 10 said they had been harmed by a loved one’s drug use.

That’s close to 160 million victims — 113 million hurt by loved one’s drinking and 46 million by their drug use, according to the survey published recently in the Journal of Studies on Alcohol and Drugs.

There are more harms than people think… They affect families, relationships and communities.William Kerr
Scientific Director, Center Director & Study Co-Author, Alcohol Research Group’s National Alcohol Research Center, Public Health Institute

He said it makes sense that risky drinking and drug use have far-reaching consequences, but researchers only began looking at the secondhand harms of alcohol in recent years. Less has been known about the damage done by a loved one’s drug use.

The new study is based on a survey of 7,800 U.S. adults. They were questioned between September 2019 and April 2020, before the pandemic became a factor in Americans’ substance use.

People were asked if they had been harmed in any of several ways due to someone else’s substance use.

In all, 34% of respondents said they had suffered secondhand harm from someone else’s alcohol use. The harms ranged from marriage and family problems to financial fallout, assault and injury in a drunken-driving accident.

Meanwhile, 14% of respondents said they’d suffered similar consequences from a loved one’s drug abuse.

The two groups overlapped, too — 30% of respondents reporting secondhand harm from alcohol also said they were affected by someone’s drug use.

Kerr said in a journal news release that the differences probably owe to the fact that drinking and alcohol use disorders are more common than drug use and disorders. But, he added, researchers want to learn more and are launching a new survey with more questions about the harms related to individual drugs.”

Source: https://www.phi.org/press/us-news-phi-study-shows-nearly-160-million-americans-harmed-by-anothers-drinking-drug-use/

MEDIA ADVISORY

WASHINGTON – Formal hearing proceedings regarding the proposed rescheduling of marijuana will begin on December 2, 2024 at 9:30 A.M. ET in the North Courtroom at DEA Headquarters located at 700 Army Navy Drive, Arlington, VA. This preliminary hearing will serve as a procedural day to address legal and logistical issues and discuss future dates for the evidentiary hearing on the merits.  No witness testimony will be offered or received at this time.

In-person attendance is limited to designated participants and credentialed members of the media who have received confirmation of their in-person attendance.

WHAT:    Commencement of formal hearing proceedings regarding the proposed rescheduling of Marijuana

WHO:    Open to designated participants and designated credentialed members of the media.

WHEN:        December 2, 2024 | 9:30 a.m. to 5 p.m.

WHERE:     DEA Headquarters | 700 Army Navy Drive, Arlington, Va. 22202 | North Courtroom

FOR MEMBERS OF THE PUBLIC: Members of the public will have access to the court sessions virtually at www.DEA.gov/live.

FOR NEWS MEDIA: News media wishing to attend in person must RSVP to DEAPress@dea.gov by 10 a.m. on November 29, 2024.  Due to limited capacity, RSVPs will be accepted on a first come, first served basis.

Designated members of the media should arrive no later than 9:00 a.m. on December 2 and follow all security screening procedures. Media credentials are required to be visible while inside DEA Headquarters. Video and audio recordings are not permitted at any time inside the courtroom.

Background:
On May 21, 2024, the Department of Justice proposed to transfer marijuana from schedule I of the Controlled Substances Act to schedule III of the CSA, consistent with the view of the Department of Health and Human Services that marijuana has a currently accepted medical use as well as HHS’s views about marijuana’s abuse potential and level of physical or psychological dependence. The CSA requires that such actions be made through formal rulemaking on the record after opportunity for a hearing. If the transfer to schedule III is finalized, the regulatory controls applicable to schedule III controlled substances would apply, as appropriate, along with existing marijuana-specific requirements and any additional controls that might be implemented, including those that might be implemented to meet U.S. treaty obligations. If marijuana is transferred into schedule III, the manufacture, distribution, dispensing, and possession of marijuana would remain subject to the applicable criminal prohibitions of the CSA. Any drugs containing a substance within the CSA’s definition of “marijuana” would also remain subject to the applicable prohibitions in the Federal Food, Drug, and Cosmetic Act. For more information, visit www.DEA.gov.

Source: https://www.dea.gov/stories/2024/2024-11/2024-11-26/dea-hold-hearing-rescheduling-marijuana

We targeted drug cartels to stop fentanyl. Now, overdose deaths are dropping. | Opinion


Anne Milgram  |  Opinion contributor

This fight may seem daunting, and it is unbearable for the families who have lost a loved one. The opioid epidemic has led to tragic deaths across the nation for decades.

In recent years, however, we’ve witnessed Americans being poisoned by fentanyl. Two Mexican cartels are responsible for almost all the fentanyl found in the United States. These cartels press fentanyl into pills to look like prescription medications and they hide fentanyl powder in other drugs like cocaine.

This deception drives addiction, leading to more sales and profit. Of the more than 107,000 drug-related deaths last year, 69% of them involved fentanyl. That is about 200 American lives lost every day to fentanyl.

But today, we are making significant progress in this battle.

Drug deaths decline by more than 14%

According to new provisional data from the Centers for Disease Control and Prevention, drug deaths in the United States have fallen for the first time in five years. The United States has seen a more than 14% decrease in deaths between June 2023 and June 2024.

While several contributors led to the decline, this marks an important milestone in DEA’s fight to save lives.

When I joined DEA more than three years ago, it was clear that this unprecedented threat required a new approach. We transformed our operations to meet the moment and quickly built a plan to attack the cartels.

We launched counter threat teams focused on a whole network approach to disrupt and defeat the Sinaloa and Jalisco cartels, the Mexican gangs responsible for the deadly influx of fentanyl and methamphetamine into the United States.

While the harm is felt in the United States, the global fentanyl supply chain spans more than 65 countries. Our goal is simple: Take action across the entire supply chain and make it impossible for the cartels to do business.

DEA’s investigations have resulted in charges against Chinese chemical companies and Chinese nationals responsible for the production and sale of chemicals used to manufacture fentanyl; the leaders, money launderers, transporters and enforcers of the Sinaloa and Jalisco cartels; thousands of individuals across the United States who work for the cartels and pedal fentanyl on social media and on our streets; and the money launderers moving billions of dollars in drug money across the globe.

DEA is proud to lead this fight to stop deadly drugs from coming into our communities. Our agency has some of the most highly skilled professionals in the world – special agents, intelligence analysts, data scientists, cyber specialists, social media analysts and forensic scientists – working together to take down these multinational criminal drug networks.

Top drug cartel leaders arrested

Working with our law enforcement partners, our approach has led to the arrests of top cartel leaders and record drug and money seizures.

Last year, DEA seized 80 million fentanyl pills and 12,000 pounds of fentanyl powder, which is the equivalent to 390 million doses. That is enough to kill every single American.

DEA has disrupted global drug trafficking operations from China to Mexico by arresting and indicting cartel members at the highest levels of leadership ‒ including Joaquin Guzman Lopez, son of notorious drug kingpin “El Chapo,” and Ismael Zambada García, or “El Mayo.”

Since 2021, four out of the seven top Sinaloa cartel members have been taken into custody, and three will soon face justice in the United States. DEA has also uncovered and taken down significant global money laundering operations, cutting off funding to the cartel’s operations.

Since launching DEA’s One Pill Can Kill campaign in 2021, we have focused on raising awareness about the dangers of fentanyl.

We also have partnered with families who have lost loved ones to fentanyl. This has been a game changer. The families have been key to sharing lifesaving information and resources in communities across the country. These parents, children, grandparents and siblings continue to turn tragedy into action by working to prevent other families from experiencing their pain.

Recently, at the National Family Summit on Fentanyl, I was thrilled to share with the families another major step in our progress in this fight. We have seen a significant drop in the lethality of counterfeit pills seized in our communities this past year. In 2023, DEA found that 7 out of 10 pills contain a deadly dose of fentanyl. Today, 5 out of 10 pills are potentially deadly.

Seeing a decline in the number of deadly pills on the streets of America is further proof that our efforts are working.

While DEA is proud of the progress we are seeing, we are focused on the work that still needs to be done. Every life lost is one too many. DEA and our partners will continue to fight every day to protect our communities and save lives.

This fight is winnable, but it requires everyone pulling in the same direction. We need everyone to educate themselves, their loved ones and their communities on the dangers of fentanyl.

Anyone can use DEA’s One Pill Can Kill resources to spread the message about the dangers of fentanyl and to educate themselves.

DEA also has recently launched a new resource for families. The Together For Families Network will serve as a one-stop shop to connect advocates and share information, because we know each of us can make a difference.

This recent news shows that together we can save lives, and that it takes all of us working together to win this fight.

Anne Milgram is the administrator of the U.S. Drug Enforcement Administration.

 

Source: https://eu.usatoday.com/story/opinion/2024/11/26/dea-drug-deaths-fentanyl-mexican-cartels/75487168007/

Illegal drugs are the source of immense human suffering. Those most vulnerable, especially young people, bear the brunt of this crisis. People who use drugs and those struggling with addiction face a multitude of challenges: the harmful effects of the drugs themselves, the stigma and discrimination they endure, and often, harsh and ineffective responses to their situation.

The global drug problem is a complex challenge affecting millions of people worldwide. According to the World Drug Report, there are nearly 300 million drug users globally.

The issue spans from individuals with substance use disorders to communities affected by drug trafficking and organized crime. The drug problem is deeply connected to organized crime, corruption, economic crime, and terrorism. To effectively address this challenge, it is crucial to adopt a science-based, evidence-driven approach that prioritizes prevention and treatment.

The drug trade problem was recognized early in the 20th century, leading to the first international conference on narcotic drugs in Shanghai in 1909. In the decades that followed, a multilateral system was established to control the production, trafficking, and abuse of drugs.

Evidence-based drug prevention programmes can safeguard individuals and communities. By reducing drug use, these programmes can also weaken the illicit economies that exploit human misery.

Types of Illegal Drugs

Drugs are chemical substances that affect the normal functioning of the body or brain. They can be legal, like caffeine, nicotine, and alcohol, or illegal. Legal drugs, such as medicines, help with recovery from illness but can also be abused. Illegal drugs are considered so harmful that international laws, under United Nations conventions, regulate their use, making it unlawful to possess, use, or sell them.

Illegal drugs often have various street names that can vary by region and change over time. Their effects include immediate physical harm and long-term impacts on psychological and emotional development, especially for young people. Drugs can impair natural coping mechanisms and potential, and mixing them can result in unpredictable and severe consequences.

Additionally, drug use can impair judgment, leading users to take risks such as unsafe sex, which increases the risk of contracting hepatitis, HIV, and other sexually transmitted diseases.

Most common illegal drugs include:

  • Cannabis;
  • Cocaine;
  • Ecstasy;
  • Heroin;
  • LSD (D-Lysergic Acid Diethylamide); and
  • Methamphetamine.

In recent years, New Psychoactive Substances (NPS) have become a global phenomenon. NPS are substances of abuse not controlled under international drug conventions, but may pose public health risks. The term “new” refers to substances recently introduced to the market, not necessarily newly invented.

Known as “designer drugs,” “legal highs,” or “bath salts,” NPS often mimic the effects of illicit or prescription drugs. They are created by modifying the chemical structures of controlled substances to bypass legal restrictions.

The rapid appearance of diverse NPS on the global market poses public health risks and challenges for drug policy. Limited knowledge about their effects complicates prevention and treatment efforts, while their chemical diversity makes identification and analysis difficult. Effective monitoring, information sharing, and early warning systems are critical for addressing these challenges.

UN Action

Since its founding, the United Nations has been tackling the global drug problem in a systematic manner.

The United Nations Commission on Narcotic Drugs (CND) was established in 1946 by the Economic and Social Council (ECOSOC) through resolution 9(I). Its purpose is to assist ECOSOC in overseeing the implementation of international drug control treaties.

Three drug control conventions were adopted under the auspices of the United Nations (in 1961, 1971 and 1988). Adherence is now almost universal.

The International Narcotics Control Board (INCB) is an independent, quasi-judicial expert body established under the 1961 Single Convention on Narcotic Drugs. It was formed by merging two earlier organizations: the Permanent Central Narcotics Board, created by the 1925 International Opium Convention, and the Drug Supervisory Body, established under the 1931 Convention for Limiting the Manufacture and Regulating the Distribution of Narcotic Drugs. The INCB monitors and assists governments in complying with international drug control treaties.

The World Health Organization (WHO) is a key player in the United Nations’ efforts to combat the global drug problem. Sustainable Development Goal 3, specifically Target 3.5, calls on governments to enhance prevention and treatment programs for substance abuse. WHO’s approach to addressing the global drug problem focuses on five key areas: prevention, treatment, harm reduction, access to controlled medicines, and monitoring and evaluation.

The United Nations Office on Drugs and Crime (UNODC) supports governments in implementing a balanced, health- and evidence-based approach to the world drug problem that addresses both supply and demand and is guided by human rights and the agreed international drug control framework. This approach involves: treatment, support, and rehabilitation; ensuring access to controlled substances for medical purposes; working with farmers who previously cultivated illicit drug crops to develop alternative sustainable livelihoods for them; and establishing adequate legal and institutional frameworks for drug control through using international conventions. UNODC works in all regions through balanced, evidence-based responses to address drug abuse and drug use disorders, as well as the production and trafficking of illicit drugs.

Recent Milestones

In 2009, governments adopted the Political Declaration and Plan of Action on International Cooperation Towards an Integrated and Balanced Strategy to Counter the World Drug Problem, which includes goals and targets for drug control.

Progress towards addressing the world drug problem and related issues is assessed at the United Nations General Assembly Special Session (UNGASS). All nations are encouraged to keep in mind the key principles of the 2030 Agenda for Sustainable Development and to leave no one behind. The Special Session in 2016 resulted in an outcome document, Our joint commitment to effectively addressing and countering the world drug problem.

In 2019, the Commission on Narcotic Drugs adopted the Ministerial Declaration on Strengthening actions at the national, regional and international levels to accelerate the implementation of joint commitments made to jointly address and counter the world drug problem. In the Declaration, governments reaffirmed their determination “to address and counter the world drug problem and to actively promote a society free of drug abuse in order to help ensure that all people can live in health, dignity and peace, with security and prosperity, and reaffirm our determination to address public health, safety and social problems resulting from drug abuse.” They also decided to review the progress made in implementing the policy commitments in 2029.

Global Response

National legislative frameworks govern the responses of criminal justice systems to the world drug problem. In the vast majority of countries, illicit cultivation of drug crops, diversion of precursors and drug trafficking are criminal offences, but the criminal nature of drug use or possession for use varies across countries and regions.

Drug use or possession is considered a criminal offence in about 40 per cent of the 94 countries where data are available, representing a significant proportion of the global population. Available data indicate that more punitive measures are imposed for drug use or possession in Asia compared with other regions, while the Americas and Asia are the most punitive regions for drug trafficking.

Long-term efforts to dismantle drug economies must focus on providing socioeconomic opportunities and alternatives that address the root causes of illicit crop cultivation, such as poverty, underdevelopment, and insecurity. These efforts should go beyond simply replacing illicit crops or incomes. Additionally, they must address the factors that lead to the recruitment of young people into the drug trade, as they are particularly vulnerable to synthetic drug use.

According to newly available estimates, in 2022 only about 1 in 11 people with drug use disorders received drug treatment globally. It is recommended that all individuals affected by the world drug problem, including women, who face disproportionate stigma and discrimination, are ensured their universal right to health. To achieve this, drug treatment, care, and services must be comprehensive, effective, voluntary, and accessible to everyone without discrimination. These services should be designed to uphold and preserve the dignity of all individuals, including those who use drugs, as well as their communities.

Role of Civil Society

The United Nations acknowledges the importance of fostering strong partnerships with civil society organizations to address the complex challenges of drug abuse and crime, which weaken the fabric of society. Active participation from civil society— non-governmental organizations, community groups, labour unions, indigenous groups, charitable organizations, faith-based groups, professional associations, and foundations — is crucial in supporting the UN’s efforts to fulfill its global mandates effectively.

UNODC supports NGOs participation in relevant drug-related policy discussions and meetings, particularly the CND regular and intersessional meetings and encourages the increased dialogue between NGOs, member states and UN entities, through the Vienna NGO Committee on Drugs (VNGOC).

Youth Engagement

Recognizing that youth are a vulnerable population, it is essential for the international community to address the issue of substance abuse effectively. Through the Youth Initiative, the UN provides opportunities for youth to actively participate in efforts to prevent substance use. This programme enables young people to join a community of peers committed to promoting health and well-being.

The Youth Forum is an annual event organized by the UNODC Youth Initiative as part of the broader framework of the Commission on Narcotic Drugs. It brings together young people from around the world, nominated by governments, who are actively engaged in drug use prevention, health promotion, and youth empowerment.

The forum provides a platform for participants to exchange ideas, share visions, and explore diverse perspectives on enhancing the health and well-being of their peers. Additionally, it offers an opportunity for youth to present their collective message to global policymakers, contributing their voices to international discussions and decisions.

Resources

 

Source: https://www.un.org/en/global-issues/drugs

November 29th 2024
Young people are not only the leaders of tomorrow but also a powerful force for change today. Their engagement in drug prevention efforts is crucial in not only identifying the challenges faced by the younger generation; it can also shed light on the various ways that youth can be meaningfully involved as agents of change. In this regard, the UNODC Youth Initiative is proud to have supported youth mainstreaming through the publication of “Formación en Liderazgo Juvenil para la Prevención (Youth Leadership Training for Prevention) in 2024. Featuring stories of action and contributions from UNODC Youth Forum alumni, this publication emphasizes the importance of empowering youth to take an active role in prevention, which can help to foster resilience, community cohesion, and social change.

Originally a project proposed to UNODC to highlight ‘Youth in Prevention’, the Youth Initiative extended this proposal to the alumni network of the Youth Forum, to take leverage on the opportunity to highlight and feature the commendable work done by young people. As highlighted in the publication, meaningful youth participation paves the way for innovative solutions that are tailored to the needs of adolescents, their peers, and communities. And by investing in their leadership, we create opportunities for young people to become advocates for healthier lifestyles, role models for their peers, and key contributors to building a more inclusive society.

The publication features contributions from five UNODC Youth Forum alumni who bring their unique perspectives and experiences to various dimensions of prevention. The contributors – Alexandra Bravo Schroth (Peru), Maya Nujaim(Canada), Vinayak Menon (USA), Karthika Pillai (India), and Adrian Milic (Norway) – worked collaboratively over many months to develop their contributions to the book’s chapter, “Empowering and Supporting Global Youth Participation in Prevention Activities.Through weekly virtual meetings, young leaders exchanged ideas, refined their key concepts, and supported one another in the shared goal of advocating for evidence-based prevention.

One of the contributors, Maya Nujaim from Canada, provides a compelling account of her work as a substance use prevention counselor in Montreal. Reflecting on her experiences, she shares: “Being a youth helping other youths is empowering for me, and I believe we need more young people in drug use prevention…I work with a team of young people who also want to make a difference in the lives of youth, and thanks to our life experiences and knowledge, we can easily connect with young people in schools and encourage them to participate in drug prevention activities.

Maya’s prevention activities are rooted in the key principles of the UNODC/WHO International Standards on Drug Use Prevention, ensuring a science-informed approach that strengthen social skills, address vulnerabilities, and foster open discussions amongst young people. She has seen the direct  impacts of her work, including through reductions in substance use among students, improved peer relationships and peer resistance skills, as well as increased engagement in other creative activities.

The youth contributions within the publication provide a glimpse into the diversity of youth-led and youth-focused activities and experiences as witnessed through the lens of the UNODC Youth Initiative. Further to their motivation to be active as agents of change, youth have also showcased their ability to adapt their skills and potential to meet the challenges of other youths in their local contexts. Armed with proper knowledge, skills and science, youths are truly meeting other youths and peers where they are at, and where they can best reach them. By amplifying the voices of young leaders and showcasing the substantive impact that youth can have on their peers and communities; and this publication underscores the importance of creating spaces for youth to contribute to local, national, and global prevention efforts.

UNODC commends the efforts of the youth contributors for their dedication, innovation, and leadership. To young people worldwide: this is a call to action to look around to see where you can be involved, and know that it can start small but have meaningful impact. To policy-makers and stakeholders: it is a reminder to involve youth in prevention efforts (as more than end-beneficiaries) and listen to youth in decision-making processes.

Join us in celebrating youth as agents of change and their good work in contributing towards a healthier, more resilient future for all. For more information on ‘Formación en Liderazgo Juvenil para la Prevención , please visit here.

Source: https://www.unodc.org/unodc/prevention/youth-initiative/youth-action/2024/november/from-inspiration-to-action_-5-youth-forum-alumni-champion-prevention-efforts.html

     Too many families know the pain of losing a loved one to a drunk or drug-impaired driving accident.  Each year, more than 10,000 Americans lose their lives in these preventable tragedies.  During National Impaired Driving Prevention Month, we remind everyone that they can save lives by driving only when sober, calling for a ride, planning ahead, and making sure friends and loved ones do the same.

In 2022, over 13,000 people were killed in drunk-driving accidents.  Still, millions of people drive under the influence each year, not only putting themselves in harm’s way but also endangering passengers, pedestrians, and first responders. Even just one drink or one pill can ruin lives.

My Administration is committed to preventing accidents and impaired driving.  The National Highway Traffic Safety Administration has raised awareness about its risks and consequences through media campaigns, including “If You Feel Different, You Drive Different”; “Drive Sober or Get Pulled Over”; and “Buzzed Driving is Drunk Driving.”  Furthermore, since the beginning of my Administration, we have dedicated over $100 billion to disrupt the flow of illicit drugs and expand access to the prevention and treatment of substance use disorder.

Reducing fatalities and injuries in impaired driving accidents also means improving the safety of our Nation’s vehicles.  That is why my Bipartisan Infrastructure Law invests in technologies that can detect and prevent impaired driving and requiring new passenger cars to include collision warnings and automatic braking to prevent accidents.  The Department of Transportation also released a National Roadway Safety Strategy to eliminate traffic deaths and make crashes less destructive.

This holiday season, let us recommit to doing right by our neighbors, friends, and families by driving sober.  For those planning on drinking, arrange a sober ride home beforehand — ride-sharing apps are a convenient way to get home safely.  If you have had alcohol or used substances, do not get behind the wheel — one accident can cost someone their life.  If you are responsible for driving yourself or others, stay sober, buckle up, put the phone away, and drive the speed limit.  And if you witness a friend, loved one, colleague, or anyone putting themselves or others in danger, lend a hand to keep them safe. You could save a life.

NOW, THEREFORE, I, JOSEPH R. BIDEN JR., President of the United States of America, by virtue of the authority vested in me by the Constitution and the laws of the United States, do hereby proclaim December 2024 as National Impaired Driving Prevention Month.  I urge all Americans to make responsible decisions and take appropriate measures to prevent impaired driving.

IN WITNESS WHEREOF, I have hereunto set my hand this twenty-ninth day of November, in the year of our Lord two thousand twenty-four, and of the Independence of the United States of America the two hundred and forty-ninth.

JOSEPH R. BIDEN JR.

 

Source: https://www.whitehouse.gov/briefing-room/presidential-actions/2024/11/29/a-proclamation-on-national-impaired-driving-prevention-month-2024/

 

These TC experts emphasize the critical need for a more proactive approach to substance use education

More than 40,000 youth used nicotine pouches last year alone, a staggering increase from 2021. The relatively new and less detectable product’s increasing prevalence among youth underscores an urgent need for informed discussion and intervention regarding adolescent substance use more broadly. Data shows that 59 percent of people 12 or older used tobacco, vaped nicotine, alcohol or illicit drugs in 2023, despite proof that substance use during these formative years poses a severe threat to cognitive function. “Early drug use can impair neurocognitive development and increase youth vulnerability to later use of illicit substances, and even academic failure,” shares John Allegrante, the Charles Irwin Lambert Professor of Health Behavior and Education at Teachers College, who examines the topic in his latest research with an international group of Nordic investigators.“With each generation, the messaging and campaigns around these dangerous products change to target those most vulnerable: our youth. We [educators] need to work with parents to provide more support resources and surveillance during such critical years.”We spoke with Allegrante and other TC experts about the risks and ways educators, parents and communities can address these challenges together.

 

A Call to Action: Reimagining Awareness, Prevention, and Intervention 

While interventions like the “Just Say No” campaign and the D.A.R.E. programs of the ’80s and ’90s have proven to be unsuccessful, the desire for more effective and youth-informed approaches to preventing  substance use among youth in the U.S. continues to grow.

Influencer marketing and social media promotions for e-cigarettes have increased the risk of youth vaping. Studies show that social media platforms often glamorize e-cigarettes with trendy flavors like cotton candy, attracting young users. TC’s Ayorkor Gaba, Assistant Professor of Counseling & Clinical Psychology, notes that there is a rise in innovative approaches, like media literacy education, to help youth critically analyze media and reject harmful messages.

She explains that social media can also share science-based health messages, enhancing prevention and treatment of substance use.  For example, influencers frequently share their lived experience with overdose,  the harmful effects of vaping, and recovery. Though “impactful,” the overall quality, accuracy and reliability of this content posted can be poor. “The lack of evidence-based content on social media reinforces the need for expert involvement (e.g., public health, psychology, etc.) in disseminating evidence-based content on social media,” notes Gaba. “Due to the significant influence of social media on youth, experts and researchers should integrate youth perspectives in developing social media-based intervention and prevention that can reach millions of youth. “

The CDC notes that a high majority of adolescent substance use (81 percent) occurs during socialization with friends. “As teens, we’re all looking to fit in,” adds TC doctoral student Treasure Tannock. “Between ages 15-25, we seek to cling to anything that gives us a better understanding of self-identity. If we can use that same mindset better to reach young people about the dangers of use through a more holistic, relatable lens, we might be able to make progress.”

To start, Tannock recommends getting youth involved in creative outlets that pique their interest, a concept she implemented during her clinical work at Rikers Island. “We asked individuals: Who are you now? Who do you want to be? What obstacles do you face with substance use? And how can you receive support?” explained Tannock, a Clinical Psychology student. “We then collaborated with music and art therapists to help express their stories. Over time, many became open to support and envisioned a new path forward.”

 

How Parents, Schools and Communities Can Help

Although there is much work to be done, parents, communities and educators can start by laying the groundwork for more proactive dialogue and means of support. 

Allegrante explains that during the pandemic, increased supervision at home led to a decrease in adolescent substance use, an observation from his post-pandemic research. “As young people return to school and socialize more, we’re seeing a resurgence in use,” he explains. “Many prevention efforts start too late; by the time we address it, habits are ingrained. We must start these conversations in middle or even elementary school.”

With so much at stake, schools are tasked with a greater responsibility to address the crisis. A recent survey by the American Addiction Centers revealed that schools are the primary setting where youth receive informative substance use education. However, out of the 500 students surveyed, only 75 percent had a substance-use-focused curriculum in their health class. 

“School is still a prime captive audience location for prevention, but it requires an interdisciplinary approach, resources and a theory-driven, evidence-based curriculum across the board,” Allegrante adds. “We need to work with communities, public health agencies and even local government officials to bridge the gap.”

Yet, prevention must extend beyond the classroom. It’s imperative for parents to stay informed about their children’s habits, as research shows that parental involvement is key to mitigating peer pressure and promoting informed decision-making. “Parenting practices (e.g., monitoring, communication) have been linked to youth substance use, yet there are few accessible supports to help the busy parent develop skills in this area. Gaba recommends an app by the Substance Abuse Mental Health Services Administration called “Talk. They Hear You.,” specifically designed to help parents and caregivers turn everyday situations into opportunities to discuss alcohol and drugs with their children. “It gives them the skills, confidence, and knowledge to start and maintain these conversations as their kids grow.”

Gaba also highlights the need to address disparities,  urging, “It’s a matter of life and death.” Between 2018 and 2022, drug overdose deaths among youth more than doubled, particularly impacting Latinx and Black communities. “Many still mistakenly believe opioids do not affect these groups, leading to decreased awareness and access to vital resources like Naloxone (Narcan), which can reverse overdoses,” she notes. “Additionally, substance use is notably higher among lesbian, gay, and bisexual (LGB) youth compared to their non-LGB peers.” To address these challenges, Gaba advocates for culturally tailored interventions that actively involve marginalized youth in the design process and target the social determinants of health that contribute to their elevated risks.

“Community support is also vital,” notes Tannock. “Having safe, accessible community spaces like libraries or after-school programs can make a significant difference. It’s a team effort.” She urges parents to inquire about local prevention resources. 

Although substance use among youth is an ongoing challenge, the National Institute on Drug Abuse (NIH) reports that adolescent substance use continues to fall below pre-pandemic levels, an encouraging statistic.

“If we look at how drastically cigarette smoking has declined as a consequence of culture change, especially in advanced economies of the world, it’s a testament to just how far we’ve come,” concludes Allegrante. “But it took a concerted effort over many years, and we can certainly chart a similar path forward with this next generation.”  — Jacqueline Teschon

Source: https://www.tc.columbia.edu/articles/2024/november/why-we-need-to-modernize-substance-use-education/

Back to top of page - Back to Parents

Powered by WordPress